Navigation Links
Rigel Announces Third Quarter 2009 Financial Results
Date:11/3/2009

ucting underwriting discounts and commissions, and offering expenses.

R788 in RA Clinical Update

Last week, Rigel met with representatives of the U.S. Food and Drug Administration (FDA) to discuss the clinical profile of R788, and Rigel's proposed Phase 3 development plan for patients with rheumatoid arthritis. As a result of that meeting, Rigel expects to move forward with the plan it proposed to the FDA, including the initiation of a Phase 3 trial in the first half of 2010, pending the completion of a collaboration agreement. Rigel plans to interact with representatives of the European Medicines Agency (EMEA) by the end of 2009 to discuss the European approval requirements.

"Our recent successful public offering following the completion of our Phase 2b trials indicates that interest in our clinical programs, and R788 in particular, remains strong," said James M. Gower, chairman and chief executive officer of Rigel. "We still expect to enter into a corporate collaboration agreement before initiation of our planned Phase 3 trial of R788 in rheumatoid arthritis patients in the first half of 2010," he added.

About Rigel

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue further clinical development of R788
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces Presentations at Two Investor Conferences
2. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
3. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
4. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
9. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
10. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today ... for an exclusive licensing option to a set ... that can form the basis of a novel ... platform mitochondrial mutation detection technology will be evaluated ... evaluates and quantitates the presence of low-level mitochondrial ...
(Date:12/17/2009)... Technologies, Inc. (formerly NTII) ("NTI") announced today ... the Secretary of State of the State of ... Dissolution generally become effective upon filing. The Certificate ... under the Delaware General Corporation Law. In ... Dissolution, NTI also closed its stock transfer books ...
(Date:12/17/2009)... -- The Dr. Paul Janssen Award for Biomedical ... The $100,000 Award recognizes individuals whose efforts have ... human health. Nomination forms are available at ... February 15, 2010. The Award winner is chosen ... top scientists, which features three new members this ...
Breaking Medicine Technology:Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 2Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 3Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 4Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 2Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 3Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 4DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call 5704 1DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call 5704 2Csuy Named Senior Vice President General Merchandise Manager 5702 1Csuy Named Senior Vice President General Merchandise Manager 5702 2Does Diabetes Slow Alzheimers 3F 60110 1Does Diabetes Slow Alzheimers 3F 60110 2
... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... Administration (FDA) has issued an approvable letter for,the ... patients with community-acquired pneumonia (CAP)., Before granting ... to support the safety and efficacy of TYGACIL ...
... in ... treatment-experienced patients -, BRISBANE, Calif., May 29 InterMune, ... dosing in its Phase 1b,clinical trial evaluating ITMN-191, designated R7227 ... and,Copegus(R) (ribavirin) in treatment-naive patients infected with chronic,hepatitis C virus ...
Other Medicine Technology:Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 2Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 3Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 4Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 5Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 6InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 2InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 3InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 4
(Date:12/17/2009)... disease (IBD) research were awarded the Crohn,s & Colitis ... Advances in Inflammatory Bowel Diseases Clinical & Research Conference ... , ... New ... and scientific thought-leaders in inflammatory bowel disease (IBD) research ...
(Date:12/17/2009)... pain is now available in Rockville and Gaithersburg, Maryland. This ... sometimes even fall asleep during their treatment. , ... ... Maryland can now rejoice as The Spinal Correction & Wellness Center ... discs., , ,Humans are constantly under pressure from gravitational forces which ...
(Date:12/17/2009)... Dec. 17 Reportlinker.com announces that ... in its catalogue: ,, http://www.reportlinker.com/p0169956/Top-Ten-Worlds-Leading-Animal-Health-Companies.html ... provide the animal health industry executives with ... critical to the development and implementation of ... major objectives include: ,, To ...
(Date:12/17/2009)... LOS ANGELES, Dec. 17 On the heels ... course for the 2010 race, LA Marathon officials ... 60 non-profit organizations raising funds for causes ranging from ... waters. ,, The expanded charity program is in line ... believes the Marathon has the potential to be a ...
(Date:12/17/2009)... feature is by Devon Herrick, PhD, Senior Fellow at ... often assume they have little control over how much ... cannot be scheduled, doctors prescribe treatments and employers provide ... However, there are many overlooked ways to trim your ... ,, Cut your prescription costs: ...
Breaking Medicine News(10 mins):Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 2Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 3Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 4Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 5Health News:Rockville and Gaithersburg Now Has Spinal Decompression Therapy 2Health News:Rockville and Gaithersburg Now Has Spinal Decompression Therapy 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 4Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4
... is supporting and has agreed to work as a ... the Universal Birth Registration campaign (UBR) launched by Plan India ... unveiled a poster at an event at India Habitat Centre ... Oudmayer, country director of Plan International (India), were present at ...
... days more for the review conference on the UN five year ... not encouraging. // The United Nations has made no bones that ... in many areas, which might deter the achievement of the 2010 ... calls for a global integrated effort that is powerful and well ...
... Punjab, Haryana and Chandigarh, who are agitating against hike ... they were contemplating 'drastic steps' to draw the Centre's ... region today remained crippled causing immense hardships to patients. ... attention of the Government. Our protests so far have ...
... underwent a minor surgical procedure on his left wrist at ... ,'The operation on the left wrist follows a ... This completes the procedure advised by doctors to relieve pressure ... advisor Sanjaya Baru said in a statement., ,After the ...
... suffering from high blood pressure, heart disease and a ... the arteries // , overactive thyroid gland not to ... because there is an increase in the number of ... Canada also asked the patients to consult their doctors ...
... study conducted by Readers Digest Magazine for a poll it ... and psychic powers. // About 50% of them said that ... surveyed about 1,006 adults and 43% said that they could ... expert. About 50% said that they had dreamt of an ...
Other Medicine News:Health News:Actor Anil Kapoor Supports Birth Registration Cause 2
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Medicine Products: